At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Pre-Mkt 06-10 09:00:02 EDT
0.5800
+0.0044
+0.76%
盘前0.5571
-0.0229-3.95%
08:39 EDT
High0.5800Low0.5410Vol310.14K
Open0.5710D1 Closing0.5756Amplitude6.78%
Mkt Cap19.38MTradable Cap5.92MTotal Shares33.41M
T/O174.49KT/O Rate3.04%Tradable Shares10.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pasithea says FDA grants orphan drug designation for PAS-004 in ALS
Reuters  ·  06-02
Pasithea says FDA grants orphan drug designation for PAS-004 in ALS
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of Pas-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
THOMSON REUTERS  ·  06-02
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of Pas-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
TIPRANKS  ·  05-30
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?
Simply Wall St.  ·  05-24
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
TIPRANKS  ·  05-21
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate
Benzinga  ·  05-16
Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate
Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-16
Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  05-16
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026
Reuters  ·  05-16
Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  05-12
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
Reuters  ·  05-06
Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
TIPRANKS  ·  05-05
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
Pasithea Therapeutics names Kartik Krishnan chief medical officer
Reuters  ·  05-04
Pasithea Therapeutics names Kartik Krishnan chief medical officer
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  04-21
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
GlobeNewswire  ·  04-20
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
Reuters  ·  04-18
Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP
Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  04-03
Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
GlobeNewswire  ·  04-01
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Reuters  ·  04-01
Pasithea Therapeutics Corp expected to post a loss of 45 cents a share - Earnings Preview
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock
Simply Wall St.  ·  03-25
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock

Introduction

Company Name.
Pasithea Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Issue price:
--